|
IGF::OT::IGF Division of Cancer Prevention, Information Technology and Informatics Support Option 1 Period of Performance 09/22/2017 - 09/21/2019
|
261201500002B
|
$3,351,670
|
-, -
|
INFORMATION MANAGEMENT SERVICES, INC.
|
|
Frameshift peptide vaccine for the prevention Lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 to 3/16/2021
|
261201500039I
|
$894,832
|
-, -
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
IGF::OT::IGF Topic 378: mPROS: Mobile PRO-CTCAE Administration System for Post-Radiation Toxicities
|
261201800013C
|
$224,995
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
Topic 374 - Phase I - Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention
|
261201800035C
|
$299,810
|
-, -
|
ZYMERON CORPORATION
|
|
DOE PNNL
|
ACN15006-001
|
$800,000
|
-, -
|
UNITED STATES DEPT OF ENERGY
|
|
GENETICS AND EPIGENETICS OF SUSCEPTIBILITY TO NON-ALCOHOLIC LIVER DISEASE
|
ACN18002-001
|
$80,000
|
-, -
|
FOOD & DRUG ADMINISTRATION
|
|
NCHS SMALL AREA EST
|
APC18002-001
|
$50,000
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
5UM1CA186704-04
|
$1,703,461
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Linxian nutrition intervention trial follow-up study
|
ZIA CP000112 00377
|
$41,189
|
Abnet, Christian
|
DCEG (NCI)
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185 10318
|
$63,563
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Golestan Cohort Study
|
ZIA CP000185 10361
|
$65,336
|
Abnet, Christian
|
DCEG (NCI)
|
|
Detection of somatic, subclonal and mosaic CNVs from sequencing
|
1U24CA220242-01A1
|
$559,916
|
ABYZOV, ALEXEJ
|
MAYO CLINIC ROCHESTER
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection
|
1R21CA216807-01A1
|
$203,254
|
AGOPIAN, VATCHE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
|
5R01CA134633-06
|
$535,071
|
AHRENS, ERIC
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Role of Nix in pancreatic ductal adenocarcinoma
|
5F30CA200240-03
|
$49,524
|
ALAGESAN, BRINDA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Mesothelin-targeted immunotoxins in Pancreatic Cancer
|
ZIA BC 011652
|
$700,006
|
Alewine, Christine
|
CCR (NCI)
|
|
Clinical Support
|
ZIE BC 011653
|
$7,071
|
Alewine, Christine
|
CCR (NCI)
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
|
5F30CA220847-02
|
$49,524
|
ALI, MOIEZ
|
DUKE UNIVERSITY
|
|
Profiling signaling activity and gene expression in single, pancreatic adenocarcinoma cells using CE-RNA-Seq
|
1R01CA224763-01A1
|
$575,272
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-05
|
$575,397
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Tumor Embolization Using A Novel Catheter With Integrated Flow Regulation
|
2R44CA192428-02A1
|
$893,847
|
ALLEN, MICHAEL
|
EMBOLX, INC.
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
|
5R21CA213114-02
|
$217,282
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-05
|
$307,736
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-05
|
$661,842
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Bitter Melon Component and Colon Cancer Prevention
|
5R01CA190291-05
|
$544,710
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Womens Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S3
|
$175,562
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Identification of genomic regulatory elements in pancreas cells
|
ZIA BC 011798
|
$800,611
|
Arda, Hatice
|
CCR (NCI)
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-09
|
$1,192,031
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|